AzTrials
AzTrials

Ankylosing SpondyloarthritisPhase 3POSTURENCT01583374

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

A Phase 3 study testing Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in people with Ankylosing Spondyloarthritis, run by Amgen at 103 sites in 18 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ankylosing Spondyloarthritis
What is being tested?
Apremilast tablet 20 mg and Apremilast tablet 30 mg BID
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
490 participants
Where
103 sitesin 18 countries
Study dates
2 May 2012to 25 Oct 2018
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is ≥ 4
  • Total back pain is ≥ 4
  • On stable dose of AS medication (or lack of medication) prior to randomization and through week 24

Who cannot join

  • Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for AS

Trial locations and contacts

103 sites in 18 countries.

103 sites in 18 countries

United States20 sites
  • Austin Regional Clinic

    Austin, Texas, 78731

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois, 60611

  • MetroHealth Medical Systems

    Cleveland, Ohio, 44109

  • Klein and Associates MD, PA

    Cumberland, Maryland, 21502

  • STAT Research, Inc.

    Dayton, Ohio, 45417

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Saint Paul Rheumatology, PA

    Eagan, Minnesota, 55121

  • Rheumatology and Immunotherapy Center

    Franklin, Wisconsin, 53132

  • Klein and Associates MD, PA

    Hagerstown, Maryland, 21740

  • The Arthritis Clinic

    Jackson, Tennessee, 38305

  • University of California, San Diego

    La Jolla, California, 92093-0943

  • Ramesh C Gupta MD

    Memphis, Tennessee, 38119

  • Desert Medical Advances

    Palm Desert, California, 92260

  • Sun Valley Arthritis Center

    Peoria, Arizona, 85381

  • Advent Clinical Research Centers, Inc

    Pinellas Park, Florida, 33781

  • University of Utah Hospitals and Clinics

    Salt Lake City, Utah, 84132

  • UCSF Arthritis Center

    San Francisco, California, 94143-0326

  • Burnette & Silverfield, MDS PLC

    Tampa, Florida, 33614

  • Alastair Kennedy, MD Research

    Vero Beach, Florida, 32960

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01605

Other trials in United States

Canada9 sites
  • Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW)

    Calgary, Alberta, T2N 4Z6

  • Cividino Medicine Professional Corporation

    Hamilton, Ontario, L8N 2B6

  • Dr. William G. Bensen Medicine Professional Corporation

    Hamilton, Ontario, L8N1Y2

  • Credit Valley Professional Building

    Mississauga, Ontario, L5M 2V8

  • The Arthritis Program Research Group Inc.

    Newmarket, Ontario, L3Y 3R7

  • Rheumatology Research Associates

    Ottawa, Ontario, K1H1A2

  • Centre de Recherche Saint-Louis

    Saint-Louis, Quebec, G1W 4R4

  • Nexus Clinical Research

    St. John's, Newfoundland and Labrador, A1A 5EB

  • Toronto Western Hospital

    Toronto, Ontario, M5T 258

Other trials in Canada

Czechia8 sites
  • Revmatologie s.r.o.

    Brno, 638 00

  • ARTMEDI UPD s.r.o.

    Hostivice, 253 01

  • ARTHROMED s.r.o.

    Pardubice, 530 02

  • Revmatologicka Ambulance

    Prague, 140 00

  • Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka

    Prague, 140 59

  • Medifin a.s, Šustova

    Prague, 148 00

  • Revmatologicka Ambulance

    Sokolov, 356 01

  • PV-Medical s.r.o.

    Zlín, 760 01

Other trials in Czechia

Poland8 sites
  • Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk

    Bialystok, 15-099

  • NZOZ Osteo-Medic sc A. Racewicz J. Supronik

    Bialystok, 15-351

  • Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy

    Bydgoszcz, 85-168

  • Synexus SCM Sp. z o.o.

    Gdynia, 81-537

  • Zespol Poradni Specjalistycznych

    Lublin, 20-582

  • Prywatna Praktyka Lekarska Pawel Hrycaj

    Poznan, 61-397

  • NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna

    Torun, 87-100

  • Synexus SCM Sp. z o.o.

    Wroclaw, 50-088

Other trials in Poland

Russia7 sites
  • Research Medical Complex Vashe Zdorovie

    Kazan', 420103

  • Kemerovo Regional Clinical Hospital

    Kemerovo, 650066

  • Federal State Budget Institution "Rheumatology Research Institute RAMS"

    Moscow, 115522

  • Nizhniy Novgorod State Medical Academy of Roszdrav

    Nizhny Novgorod, 603005

  • Departmental Hospital at Smolensk Station RZhD JSC

    Smolensk, 214025

  • Regional Clinical Hospital

    Vladimir, 600023

  • Sverdlovsk Regional Clinical Hospital 1

    Yekaterinburg, 620102

Other trials in Russia

Germany6 sites
  • Charite - Universitätsmedizin Berlin

    Berlin, 12203

  • Universitatsklinikum Erlangen

    Erlangen, 91054

  • Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH

    Frankfurt, 60528

  • Schön Klink Hamburg-Eilbek

    Hamburg, 22081

  • Universitatsklinikum Heidelberg

    Heidelberg, 69120

  • Rheumazentrum Ruhrgebiet

    Herne, 44649

Other trials in Germany

Spain6 sites
  • Hospital Universitario a Coruna

    A Coruña, 15006

  • Hospital de Bellvitge

    Barcelona, 08907

  • Hospital Universitario Reina Sofia

    Córdoba, 14001

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28007

  • Corporacio Sanitaria Parc Tauli de Sabadell

    Sabadell, 08208

  • Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n

    Santiago de Compostela, 15706

Other trials in Spain

Australia5 sites
  • Emeritus Research

    Camberwell, Victoria, 3124

  • Southern Clinical Research

    Hobart, Tasmania, 7000

  • Coastal Joint Care

    Maroochydore, 4558

  • Royal Perth Hospital

    Perth, 6849

  • The Queen Elizabeth Hospital

    Woodville South, 5011

Other trials in Australia

Bulgaria5 sites
  • Diagnostic and Consulting Center Sv. Pantaleymon

    Pleven, 5800

  • National Multiprofile Transport Hospital Tzar Boris III

    Sofia, 1233

  • 17 Diagnostic and Consulting Centre

    Sofia, 1505

  • Military Medical Academy - MHAT

    Sofia, 1606

  • Diagnostic Consulting Center N4

    Varna, 9010

Other trials in Bulgaria

France5 sites
  • Hopital Ambroise-Pare

    Boulogne, 92100

  • Hopital Henri Mondor

    Créteil, 94010

  • IPROS - CHR ORLEANS - Hôpital de la Source

    Orléans, 45067

  • Hopital Cochin

    Paris, 75014

  • Groupe Hospitalier Pitié- Salpétrière

    Paris, 75651

Other trials in France

Hungary5 sites
  • Qualiclinic kft

    Budapest, 1036

  • Synexus Magyarország Kft.

    Budapest, 1036

  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum

    Debrecen, 4032

  • Pest Megyei Flor Ferenc Korhaz

    Kistarcsa, 2143

  • Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet

    Veszprém, 8200

Other trials in Hungary

Romania5 sites
  • Cristei R. Rodica - Private Medical Practice

    Brăila, 810019

  • Sf. Maria Clinical Hospital

    Bucharest, 011172

  • Emergency County Clinical Hospital

    Cluj-Napoca, 400006

  • Sf Apostol Andrei Emergency Clinical County Hospital

    Galati, 800578

  • RK Medcenter SRL

    Iași, 700127

Other trials in Romania

Estonia4 sites
  • Innomedica Medical and Research Centre

    Tallinn, 10117

  • East Tallinn Central Hospital

    Tallinn, 11412

  • Clinical Research Centre Ltd

    Tartu, 50106

  • Tartu University Hospital

    Tartu, 51014

Other trials in Estonia

United Kingdom4 sites
  • Barnsley Hospital

    Barnsley, S75 2EP

  • Royal National Hospital for Rheumatic Diseases

    Bath, BA1 1RL

  • Chapel Allerton Hospital

    Leeds, LS7 4SA

  • Nuffield Orthopaedic Centre

    Oxford, OX3 7LD

Other trials in United Kingdom

Netherlands2 sites
  • Leiden Universitair Medisch Centrum

    Leiden, 2333 ZA

  • Academisch Ziekenhuis Maastricht

    Maastricht, 6229 HX

Other trials in Netherlands

Slovakia2 sites
  • Narodny ustav reumatickych chorob

    Piešťany, 921 12

  • MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia

    Poprad, 058 01

Other trials in Slovakia

Austria1 site
  • Krankenhaus Wien-Hietzing

    Vienna, 1130

Other trials in Austria

Sweden1 site
  • Skånes Universitetssjukhus- Malmö

    Malmö, 20502

Other trials in Sweden

About this study

Official title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS

Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.

Read the detailed description

Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.

Being tested
Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo
Keywords
spondylitis, spondyloarthritis, Spondyloarthropathy, Oral preparation
Medical subject headings
Spondylitis, Ankylosing, Spondylitis, Spondylarthritis, Spondylarthropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Apremilast tablet 20 mgDrug

    Also called Otezla; CC-10004

    Apremilast 20 mg was taken orally twice a day (BID)

  • Apremilast tablet 30 mg BIDDrug

    Also called Otezla; CC-10004

    Apremilast 30 mg was taken orally twice a day

  • PlaceboDrug

    Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.

Study groups in NCT01583374
Study groupRoleWhat they receive
Apremilast 20 mgExperimentalApremilast 20 mg was taken orally twice a day (BID)
Receives: Drug: Apremilast tablet 20 mg
Apremilast 30 mgExperimentalApremilast 30 mg was taken orally twice a day
Receives: Drug: Apremilast tablet 30 mg BID
PlaceboPlacebo comparatorIdentically matched placebo tablets were taken orally twice a day
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16

    ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:

    1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
    2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain"
    3. Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
    4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

    Measured: Baseline and Week 16

Secondary outcomes (9)
  1. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24

    The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.

    Measured: Baseline and Week 24

  2. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24

    The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.

    Measured: Baseline and Week 24

  3. Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24

    ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are:

    1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale [NRS]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active
    2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain"
    3. Function (Bath AS Functional Index [BASFI] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability
    4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

    Measured: Baseline and Week 24

  4. Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24

    The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.

    Measured: Baseline and Week 24

  5. Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement

    Measured: Baseline and Week 24

  6. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24

    The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.

    Measured: Baseline and Week 24

  7. Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260

    The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3.

    0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.

    Measured: Baseline to Week 104 and 260

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase

    A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

    Measured: From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.

  9. Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

    A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

    Measured: Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2012 (estimated)
  2. Study start2 May 2012
  3. Primary completion24 Feb 2014
  4. Study completion25 Oct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
490 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01583374
Sponsor's protocol ID
CC-10004-AS-001
Other IDs
2011-001555-37
Acronym
POSTURE
Status last verified
Oct 2019
First submitted
20 Apr 2012
Last updated
12 May 2020
Data monitoring committee
Yes
Individual data sharing
Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Publications

  • Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

    PubMed 30018799
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.

    PubMed 31077258
  • Taylor PC, van der Heijde D, Landewe R, McCue S, Cheng S, Boonen A. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. J Rheumatol. 2021 Aug;48(8):1259-1267. doi: 10.3899/jrheum.201088. Epub 2021 Feb 15.

    PubMed 33589554

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in people with Ankylosing Spondyloarthritis, run by Amgen at 103 sites in 18 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 103 sites in United States, Canada, Czechia, Poland, Russia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Mar 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 (time frame: Baseline and Week 16). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01583374, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in